Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...

1st Michigan patient undergoes FDA-authorized sickle cell gene therapy

Chantez Sanford Jr., 24, of Southfield, says his life has been transformed after undergoing Lyfgenia gene therapy at Children ...

BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing

BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing Key funding milestone will power the company's push to replace trial-and-error process ...
Labroots

Technology and Process Advancements in Cell and Gene Therapy Development

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...
GEN - Genetic Engineering and Biotechnology News

ARPA-H Grants BioCurie Funds to Build Scalable Gene Therapy Manufacturing Platform

The Advanced Research Projects Agency for Health ( ARPA-H) awarded BioCurie up to $9.3 million to accelerate the development of scalable, data-driven genomic medicine production.
Fred Hutch

Scientists see foam as starting point of a path to bedside gene therapy

The special properties of methylcellulose foam could make it a vehicle for bedside genetic engineering, according to a proof-of-principle study from bioengineers at Fred Hutch Cancer Center. In the ...
The Daily Pennsylvanian

Penn Vet researchers develop gene therapy mechanisms to treat advanced stages of vision loss

Researchers at Penn’s School of Veterinary Medicine have developed new mechanisms to treat advanced forms of inherited retinal degeneration, bridging a previous gap in patient treatments. Raghavi ...
BioSpace

Why Industry Is Questioning FDA’s Data-Sharing Push in Cell and Gene Therapy

After the FDA’s first-ever public listening meeting on data-sharing in the cell and gene therapy space, new draft guidance aims to standardize the practice. But recent decisions call into question ...

Cell and Gene Therapy CDMO Market Size to be Worth USD 29.49 Billion by 2035; Growth is Driven by Increasing Number of Advanced Therapies Globally

U.S. Cell and Gene Therapy CDMO Market is projected to grow from USD 2.09 Billion in 2025 to USD 10.28 Billion by 2035 due to expanding gene and cell therapy pipelines globallyAustin, March 06, 2026 ...

Ultragenyx's gene therapy study shows ammonia reduction in rare metabolic disorder

Ultragenyx Pharmaceutical Inc. RARE shares are down on Thursday as the company reported data from its Phase 3 study of DTX301 ...

Cell and Gene Therapy Manufacturing Market to Reach USD 146.2 Billion by 2032 Amid Rising Demand for Personalized Therapies, Viral Vector Capacity, and Automated Bioprocessing ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...